Fig. 1From: Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patientsEstimated glomerular filtration rate (eGFR) changes in autosomal dominant polycystic kidney disease (ADPKD) patients from 1Â year prior to mesenchymal stromal cell (MSC) infusion up to 12Â months after the infusionBack to article page